Bone Therapeutics

Beleggen, aandelen kopen in België, informatie, koersen en analyses

Ivel
Forum verkenner
Forum verkenner
Berichten: 52
Lid geworden op: 20 jul 2020 16:54
waarderingen: 8
Contacteer:

Re: Bone Therapeutics

Bericht door Ivel »

bertje schreef:
13 okt 2020 12:49
De 3 al bijna zichtbaar in het boekje ;)

2,8 3.465 5

2,84 300 1

2,85 2.010 4

2,86 50 1

2,87 1.500 1

2,88 2.436 2

2,89 2.323 4

2,9 4.730 2

2,93 1.000 1

2,95 5.730 3
Het is al bijna zover :up:
Wat een rally :)







Volg Beursig.com op Twitter en Facebook


TomW
Forum newbie
Forum newbie
Berichten: 6
Lid geworden op: 02 jun 2020 08:47
waarderingen: 2
Contacteer:

Re: Bone Therapeutics

Bericht door TomW »

Enig idee wat er aan de hand is ?
Of is het heel laattijdige reactie op China deal ???

bertje
Forum elite
Forum elite
Berichten: 6640
Lid geworden op: 30 jul 2012 14:53
waarderingen: 1493
Contacteer:

Re: Bone Therapeutics

Bericht door bertje »

Laatste (13/10/20 - 14:04)
3,08
Wijziging (0,48)
18,46%

bertje
Forum elite
Forum elite
Berichten: 6640
Lid geworden op: 30 jul 2012 14:53
waarderingen: 1493
Contacteer:

Re: Bone Therapeutics

Bericht door bertje »

TomW schreef:
13 okt 2020 14:04
Enig idee wat er aan de hand is ?
Of is het heel laattijdige reactie op China deal ???

Morgen mogen ze voor europa praten.
https://www.meetingonthemesa.com/agenda/

dandev
Forum verkenner
Forum verkenner
Berichten: 33
Lid geworden op: 07 jan 2016 22:10
waarderingen: 8
Contacteer:

Re: Bone Therapeutics

Bericht door dandev »

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion





90% of patients show bone fusion as well as strong clinical improvements in function and pain at 24 months follow-up period with a good product safety profile







Gosselies, Belgium, 14 October 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces positive 24-month follow-up results for the Phase IIa study with the allogeneic cell therapy product, ALLOB, in patients undergoing lumbar spinal fusion procedures.

The 24-month data show a high percentage of successful lumbar vertebrae fusion of 90%. Patients also continue to experience important clinical improvements in function and pain, from as early as six months after treatment, up to the 24-month follow-up period.

“Degenerative spine disorders have a major impact on the quality of life of patients. These impacts include decreases in the stability of the spine and pain in motion,” said Dr. Alphonse Lubansu, M.D., Head of the Spinal Clinic, Erasme University Hospital, Université libre de Bruxelles. “The 24 month follow-up data of this Phase IIa clinical trial have demonstrated that patients treated with ALLOB in spinal fusion procedure show a high incidence in fusion, and benefit from a sustained, clinically meaningful improvement in function and pain throughout the 24 months following treatment together with a good safety profile. These results show that ALLOB in combination with the standard spine fusion surgery could be a promising treatment option to address the currently unmet needs of these patients.”

“This positive data for lumbar spinal fusion complements the strong Phase I/IIa results from ALLOB in patients with delayed union fractures,” said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. “These studies provide promising clinical evidence for the potential of Bone Therapeutics’ unique allogeneic cell therapy platform to address high unmet medical needs in orthopaedics and bone related disorders. We will now hold discussions with global regulators and our partners to explore a variety of options for the next stages of clinical development for ALLOB in different orthopedic indications, while pursuing the phase IIb study of ALLOB in difficult tibial fractures. In addition, the clinical results provide further evidence for the expansion of ALLOB and our platform of differentiated MSCs to other indications.”

The multi-center, open-label proof-of-concept Phase IIa study was designed to evaluate the safety and efficacy of ALLOB administered, procedure in which an interbody cage with bioceramic granules mixed with ALLOB is implanted into the spine to achieve fusion of the lumbar vertebrae. The main endpoints of the 24-month follow-up analysis included safety and radiological assessments to evaluate vertebrae fusion (continuous bone bridges) and clinical assessments to evaluate improvement in patients’ functional disability as well as reduction in back and leg pain. The study evaluated 30 patients treated with ALLOB, 29 patients attended the 24-month visit.

Radiological data was collected from CT-scans at 24 months and assessed by three external readers. It showed a successful fusion of the lumbar vertebrae in 27 out of 30 patients (90%). In addition, the remaining 3 patients showed radiological evidence of bone formation. Treatment with ALLOB also resulted in a clear and statistically significant clinical improvement in function and reduction in pain over the 24-month follow-up period. Functional disability improved from the pre-treatment baseline to 24-month by a mean score of 60% (p<0.001) on the Oswestry Disability Index(1). Back and leg pain were strongly reduced by 57 to 62% (p<0.001) and 68 to 70% (p<0.001) respectively compared to pre-treatment baseline. Treatment with ALLOB was generally well-tolerated by the patients, consistent with previous reported results.

TomW
Forum newbie
Forum newbie
Berichten: 6
Lid geworden op: 02 jun 2020 08:47
waarderingen: 2
Contacteer:

Re: Bone Therapeutics

Bericht door TomW »

Mooie resultaten (alweer). De technologie werkt echt wel ! Nu hopen dat ze de juiste keuzes maken (partners, markten, …)

El Dinero
Forum gebruiker
Forum gebruiker
Berichten: 167
Lid geworden op: 04 apr 2014 08:33
waarderingen: 36
Contacteer:

Re: Bone Therapeutics

Bericht door El Dinero »

We zouden nu toch met gemak naar 4 euro moeten kunnen gaan met dergelijke outlook.
Ik doe ze nog niet weg in elk geval

El Dinero
Forum gebruiker
Forum gebruiker
Berichten: 167
Lid geworden op: 04 apr 2014 08:33
waarderingen: 36
Contacteer:

Re: Bone Therapeutics

Bericht door El Dinero »

Gisteren winstnemingen, voor de rest nog weinig verkooporders tot 3.5
Heb er nog wat aangekocht voor de LT

Ivel
Forum verkenner
Forum verkenner
Berichten: 52
Lid geworden op: 20 jul 2020 16:54
waarderingen: 8
Contacteer:

Re: Bone Therapeutics

Bericht door Ivel »

Ziet er goed uit voor LT :D
Ik was wel verwonderd dat de koers nog zo omhoog ging na de resultaten van Allob lumbale wervelfusie, de resultaten van het 24 maanden onderzoek (90% succesvolle fusie) stonden namelijk al enkele weken in de vernieuwde bedrijfspresentatie op de website.


Deelnemen aan het forum + meer functies?

Deel kennis en vragen met duizenden beleggers,
minder advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!



Plaats reactie